GOVERNOR CORZINE AND BAUSCH & LOMB CELEBRATE GRAND OPENING OF NEW GLOBAL PHARMACEUTICAL HEADQUARTERS
MADISON – Governor Jon S. Corzine today officially welcomed Bausch & Lomb to its new global pharmaceutical headquarters in Madison, thanking the company for growing jobs in New Jersey. Bausch & Lomb’s 30,000-square-foot facility will create 70 new full-time, high-paying jobs in the Garden State.
“Bausch & Lomb’s decision to locate its pharmaceutical headquarters in New Jersey demonstrates the state remains an attractive location for major pharmaceutical companies to grow and thrive,” Governor Corzine said. “I want to thank CEO Gerald M. Ostrov and Global Pharmaceuticals President Flemming Ornskov for Bausch & Lomb’s commitment to the Garden State. New Jersey is proud to welcome Bausch & Lomb to Madison.”
New Jersey’s vibrant pharmaceutical and biotechnology industries were a key factor in Bausch & Lomb’s decision to establish its pharmaceutical headquarters in New Jersey. According to the Healthcare Institute of New Jersey, 15 of the world’s top 25 pharmaceutical companies have either World or North American headquarters or significant operations in New Jersey.
“Establishing our global pharmaceutical headquarters in New Jersey opens up opportunities to partner with other pharmaceutical companies and to drive commercialization of new products,” said Gerald M. Ostrov, CEO of Bausch & Lomb. “Our recently announced co-promotion agreement with Pfizer for prescription ophthalmics in the U.S. is the first example of how we are successfully implementing this strategy. We’re looking forward to growing our presence here, which in turn will help us bring the best possible eye health products and services to people around the world.”
While the company maintains its worldwide headquarters in Rochester, New York, and research and development in locations worldwide, this new Madison facility establishes its pharmaceutical headquarters within a global epicenter for the industry.
“As we bring new products to market, such as our recently FDA-approved Besivance™ (besifloxacin ophthalmic suspension) 0.6% for the treatment of bacterial conjunctivitis, having our global and U.S. leadership, marketing and sales teams headquartered in New Jersey is ideal,” stated Flemming Ornskov, global president of Bausch & Lomb’s Pharmaceutical business. “Not only does it provide professional development opportunities for current staff, but is also fertile ground for recruiting the best possible talent to work with us, whether as an industry partner or employee.”
Bausch & Lomb is one of the best-known and most respected healthcare brands in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company employs more than 10,000 people worldwide and its products are available in more than 100 countries.
